Search

Search Constraints

You searched for: Author/Creator Kermode, Allan

Search Results

2. 134 Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). (29th July 2019)

5. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. (October 2018)

6. Confirmed disability progression as a marker of permanent disability in multiple sclerosis. (9th June 2022)

7. Contribution of different relapse phenotypes to disability in multiple sclerosis. (February 2017)

9. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. (June 2023)

10. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. (2nd February 2021)